We have plans to grow the company substantially in the rare disease market and specifically in the therapeutic areas of oncology, haematology and endocrinology. Over the next three years, Masters will be investing in building strong regional teams to ensure that we deliver our vision. The acquisition of products in specialised therapeutic areas and companies that complement and add value to our business is another important element of Masters Speciality Pharma’s strategy.
Our experience of successfully addressing differing and often complex regulatory requirements, particularly in emerging markets, ensures that Masters are ideally placed to increase demand for both new and established products.
Strengthening our businesses overseas through the addition of experienced personnel in Central America, South America and Latin America, ensures we can confidently pursue our expansion strategy in both our existing and new markets. The focus of our recruitment has been the appointment of personnel who are experienced in the pharmaceutical industry and understand the access programs that operate in their territories, working with regulators to register products compliantly and efficiently.
Regulatory compliance is key to our business and we recognise the importance of operating in an ethical and legal way. As a consequence of this we have on our Executive team a Director of Quality Assurance and Regulatory, whose role it is to deliver service excellence across the group and provide customer reassurance, ensuring that we work with our Partners transparently, guard against diversion and protect product integrity.
In addition to increasing our operational capacity, Masters has recently undergone a significant corporate rebranding exercise spearheaded by our growing in-house marketing team. We believe as a consequence of these and other strategic initiatives, Masters is well positioned to ensure solid future growth and enhanced shareholder value.